Novavax Stock Surges 8% on New Partner-Led Growth Strategy
Novavax shares rallied sharply after unveiling a strategic pivot at the J.P. Morgan Healthcare Conference. The biotech firm's 8% gain reflects investor approval of its shift toward collaborative commercialization and cost discipline.
The revised approach centers on three pillars: expanded pharmaceutical partnerships, operational efficiency measures, and diversified R&D investment. A landmark deal with Sanofi serves as the cornerstone of this partner-first model.
Market response was immediate, with the stock climbing to $7.75 in active trading. This extends a 9% two-week advance, marking one of the security's strongest performances since last quarter.